Valneva (NASDAQ:VALN) Sees Strong Trading Volume

Valneva SE (NASDAQ:VALN) saw unusually-high trading volume on Thursday . Approximately 34,850 shares changed hands during mid-day trading, an increase of 279% from the previous session’s volume of 9,184 shares.The stock last traded at $7.61 and had previously closed at $7.75.

Analyst Upgrades and Downgrades

VALN has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of Valneva in a research report on Thursday, March 21st. Guggenheim reduced their price target on Valneva from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, March 22nd.

Valneva Price Performance

The company has a debt-to-equity ratio of 1.04, a current ratio of 1.65 and a quick ratio of 1.37. The company has a 50-day moving average price of $7.64 and a two-hundred day moving average price of $9.50.

Valneva (NASDAQ:VALN) last posted its earnings results on Wednesday, March 20th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of $0.20 by ($0.70). Valneva had a negative return on equity of 59.48% and a negative net margin of 65.99%. The business had revenue of $45.12 million for the quarter, compared to analysts’ expectations of $45.06 million. As a group, equities research analysts predict that Valneva SE will post 0.11 earnings per share for the current year.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.